NSE: AARTIDRUGS | BSE: 524348

Strong Performer, Getting Expensive

Download real time

504.85 -1.55 (-0.31%)

61.81% Gain from 52W Low

64,505 NSE+BSE Volume

NSE 08 Oct, 2025 3:31 PM (IST)

4,607.8

Market Cap

Above industry Median

0.9

Beta 1Year

Low volatility

Aarti Drugs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AARTIDRUGS, BSE:524348 Aarti Drugs Ltd.

Aarti Drugs Ltd.

02 May 2023

504.85

-0.31%

Company Outlook & Guidance: Most of the API players reported an increase in volume uptick backed by improved demand and stable realisations. We expect demand for API to continue in the upcoming quarters with the ease of supply chain bottlenecks. Aarti Drugs, being a leader in the domestic industry,

Aarti Drugs Ltd. has gained 56.91% in the last 6 Months

Aarti Drugs Ltd.

31 Jan 2023

504.85

-0.31%

Result Update:Aarti Drugs

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We recommend a BUY rating on the stock

Aarti Drugs Ltd. has an average target of 475.00 from 1 broker.

Aarti Drugs Ltd.

30 Oct 2022

504.85

-0.31%

Result Update:Aarti Drugs

Buy: Aarti Drugs Ltd.

Recommendation Target

Axis Direct

Aarti Drugs could be benefitted in upcoming quarters, we upgrade to BUY on Aarti Drugs with Target Price of Rs 545

Aarti Drugs Ltd. has an average target of 475.00 from 1 broker.

Aarti Drugs Ltd.

11 May 2022

504.85

-0.31%

Result Update:Aarti Drugs

Hold: Aarti Drugs Ltd.

Target

Axis Direct

We believe the company's profitability might be hit due to the above factors, prompting us to recommend a HOLD rating on the stock with TP Rs 450/share.

Aarti Drugs Ltd. has gained 56.91% in the last 6 Months

Aarti Drugs Ltd.

02 Feb 2022

504.85

-0.31%

Result Update:Aarti Drugs

Hold: Aarti Drugs Ltd.

Target

Axis Direct

Furthermore, the raw material prices for API manufacturing have shown softness which will support the company's growth in the upcoming quarters. We recommend HOLD with the target price of Rs 540/share.

Number of FII/FPI investors decreased from 96 to 73 in Jun 2025 qtr

Aarti Drugs Ltd.

29 Oct 2021

504.85

-0.31%

Result Update:Aarti Drugs

Hold: Aarti Drugs Ltd.

Recommendation Target

Axis Direct

We believe this trend will continue for the upcoming quarters and therefore recommend HOLD rating 0n the stock with a Target Price of Rs 645/share.

Aarti Drugs Ltd. has an average target of 475.00 from 1 broker.

Aarti Drugs Ltd.

29 Jul 2021

504.85

-0.31%

Result Update:Aarti Drugs

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We expect revenue and PAT CAGR of 13.3% and 12.3% respectively over the period FY21-FY23E and recommend BUY with TP of Rs 760.

Aarti Drugs Ltd. has an average target of 475.00 from 1 broker.

Aarti Drugs Ltd.

18 May 2021

504.85

-0.31%

Result Update:Aarti Drugs

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We expect revenue and PAT CAGR of 15.9% and 15.3% respectively over the period FY21-FY23E and recommend a Buy with TP of INR 840.

Number of FII/FPI investors decreased from 96 to 73 in Jun 2025 qtr

Aarti Drugs Ltd.

28 Jan 2021

504.85

-0.31%

Result Update:Aarti Drugs

Buy: Aarti Drugs Ltd.

Target

Axis Direct

We expect revenue and PAT CAGR of 18.2% and 37.6% respectively over the period FY20-FY23E and recommend Buy with TP of INR 812.

Aarti Drugs Ltd. has gained 56.91% in the last 6 Months

Aarti Drugs Ltd.

07 Dec 2020

504.85

-0.31%

Pick of the Week:7 DEC 2020

Buy: Aarti Drugs Ltd.

Target

Axis Direct

ARTD is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) Pharma Intermediates and Specialty Chemicals. Products under APIs includes Ciprofloxacin, Hydrochloride, Metronidazole, Metformin HCL, etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotin

Aarti Drugs Ltd. is trading above all available SMAs

Is Aarti Drugs Ltd. worth buying?

746 Votes:

Buy 77.88%

Sell 11.39%

Hold 10.72%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf